Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias

CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the initiation of an exploratory Phase 2 program of AKCEA-ANGPTL3-LRx in patients with rare hyperlipidemias.

AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3, or ANGPTL3. The absence of ANGPTL3 has been shown to be cardioprotective and associated with reduced risk of insulin resistance and diabetes mellitus. 

The AKCEA-ANGPTL3-LRx Phase 2 program is designed to include three clinical studies in patients with one of three rare hyperlipidemias, including familial chylomicronemia syndrome (FCS), familial partial lipodystrophy (FPL), and homozygous familial hypercholesterolemia (HoFH). The objectives of these studies are to determine the pharmacodynamics, pharmacokinetics, safety and tolerability of AKCEA-ANGPTL3-LRx, and to further characterize the drug’s potential in these patient populations.

Prev1 of 9

Other articles you might like;

Leave a Reply

Your email address will not be published. Required fields are marked *